Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative MPNs
NCT06661915Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iadademstat in Myeloproliferative Neoplasm (MPN) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Acute leukemia response-complete rate. Started Aug 2025; status: recruiting.
02
Drugs
iadademstat
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT06661915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06661915.